U.S. Department of Justice informs Viatris that it no longer considers Mylan the subject of an antitrust investigation into the generics industry

PITTSBURGH, July 2, 2024 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice (“DOJ”) has indicated that it is no longer considering Mylan and its former CEO Rajiv Maliksubject of an antitrust investigation into the generic drug industry. The DOJ Civil Division also informed the Company that it does not expect to take further action with respect to the civil investigational demand regarding the pricing and sales of generic drug products.

This finding confirms the Company’s long-standing position that Mylan thoroughly investigated these allegations and found no evidence of any wrongdoing by Mylan or its employees.

The Company is pleased to put the DOJ investigations aside and will continue to vigorously defend itself against the remaining civil lawsuits related to these matters. Please see Viatris’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 For more information on drug prices.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generic and branded medicines, combining the best of both to more holistically address healthcare needs around the world. With a mission to empower people everywhere to live healthier lives at every stage of life, we deliver access at scale, currently delivering high-quality medicines to approximately 1 billion patients worldwide annually, touching every stage of life, from birth to end of life, from acute to chronic. With our uniquely broad and diverse portfolio of medicines, a unique global supply chain designed to reach more people when and where they need them, and scientific expertise to address some of the world’s most enduring health challenges, access is deeply important at Viatris. Headquartered in the United States, we have global centers in Pittsburgh, Shanghai AND HyderabadIndia. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

Forward-looking statements
This release includes statements that constitute “forward-looking statements.” These statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the outcomes of investigations and legal proceedings and that the Company is pleased to put these Department of Justice investigations behind it and will continue to vigorously defend any remaining civil lawsuits related to these matters. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulatory authorities; changes in healthcare and pharmaceutical laws and regulations in the United States and abroad; any regulatory, legal or other impediments to Viatris’ ability to bring new products to market, including, but not limited to, “distressed” launches; the ability of Viatris or its partners to develop, manufacture and commercialize products; the scope, timing and results of any ongoing legal proceedings and the impact of any such proceedings; the possibility that Viatris will not be able to realize intended benefits or achieve intended goals or prospects with respect to its strategic initiatives; the possibility that Viatris will not be able to achieve intended or expected benefits, goals, prospects, synergies, growth opportunities and operating efficiencies from any divestitures, acquisitions, other transactions or restructuring programs, within the expected timeframes or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the failure of Viatris to achieve expected or projected future financial and operating results; the potential impact of public health outbreaks, epidemics and pandemics; any material breaches of data security or data privacy or disruptions to our information technology systems; risks related to our international operations; the ability to protect and retain intellectual property rights; changes in our relationships with third parties; the impact of any changes in Viatris’ or its partners’ customer and supplier relationships and customer purchasing patterns; the impact of competition; changes in Viatris’ or its partners’ economic and financial conditions; uncertainties and matters beyond the control of management, including general economic conditions, inflation and currency exchange rates; failure of Viatris to repurchase shares in accordance with current expectations; stock price volatility; and other risks described in Viatris’ filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusive manner for purposes of SEC Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements to reflect changes or corrections after the date of this release, except as required by law.

SOURCE Viatris Inc.